Press Releases

AMA applauds FDA for approving naloxone product to prevent overdoses

| 2 Min Read

“The American Medical Association (AMA) applauds the Food and Drug Administration (FDA) for approving the nasal spray version of naloxone, a life-saving medication that can reverse the effects of an opioid overdose by restoring breathing and preventing death. The FDA’s swift action will widely increase accessibility to this medication that will help prevent more opioid-related overdoses and save more lives.

“The AMA has long advocated in support of a multi-pronged approach to addressing prescription drug abuse and diversion, which includes increasing access to naloxone for patients who need it.

Full press statement available when you sign in

Sign in to the AMA website to get the full version of this press statement. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Abe Sutton, JD, CMS director, on the AMA Moving Medicine video podcast

New voluntary CMS pay model encourages use of health tech

| 5 Min Read
Young adult in a telehealth appointment

New data details how telehealth use varies by physician specialty

| 4 Min Read
Mom holding baby gets medicine from doctor

The AMA is committed to reversing the maternal mortality crisis

| 5 Min Read
Young child  holding throat with pained expression

What doctors wish patients knew about strep throat

| 11 Min Read